Table 3 Biomarkers in the dose escalation cohorts (baseline normalised to 1)

From: Pazopanib exposure decreases as a result of an ifosfamide-dependent drug–drug interaction: results of a phase I study

Ifosfamide schedule

Biomarker

Pazopanib dose

Baseline

After 7 days pazopanib but prior to first ifosfamide

Prior to second ifosfamide

CIV

PlGF

400

1

1.75

1.35

  

800

1

6.87

8.46

  

1000

1

7.13

4.39

 

VEGF-A

400

1

1.08

0.54

  

800

1

5.26

5.72

  

1000

1

3.85

2.73

 

sVEGFR2

400

1

0.89

0.88

  

800

1

0.77

0.70

  

1000

1

0.76

0.69

BIV

PlGF

200

1

1.81

1.75

  

400

1

2.40

3.24

 

VEGF-A

200

1

1.72

3.12

  

400

1

1.96

2.20

 

sVEGFR-2

200

1

0.89

0.81

  

400

1

0.79

0.77

  1. Abbreviations: BIV=bolus intravenous infusion; CIV=continuous intravenous infusion; PlGF=placental-derived growth factor; sVEGFR2=soluble VEGFR2; VEGF-A=vascular endothelial growth factor-A.
Back to article page